Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...
The majority of working-age patients with postacute sequelae of COVID-19/post-COVID-19 syndrome (PCS) do not recover in the second year of their illness.